Cowen Prime Advisors’s Pharming Group PHAR Stock Holding History

Cowen Prime Advisors’s Portfolio PHAR Stock Details PHAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$262K	Hold	22,460	–	–	0.09%	76
2023 Q1	$250K	Buy	22,460 +850	+4%	+$10.7K	0.1%	79
2022 Q4	$238K	Buy	21,610 +4,910	+29%	+$54.3K	0.1%	80
2022 Q3	$164K	Buy	16,700 +200	+1%	+$2.02K	0.09%	77
2022 Q2	$145K	Buy	16,500 +650	+4%	+$5.32K	0.08%	85
2022 Q1	$142K	Buy	15,850 +1,050	+7%	+$9.31K	0.06%	90
2021 Q4	$132K	Buy	14,800 +8,500	+135%	+$75.3K	0.04%	90
2021 Q3	$60K	Hold	6,300	–	–	0.02%	114
2021 Q2	$71K	Buy	+6,300	New	+$78.4K	0.03%	107

Other funds holding PHAR

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cowen Prime Advisors's PHAR Position: Q2 2023 in Review

Cowen Prime Advisors held its Pharming Group (PHAR) position steady in Q2 2023 at 22,460 shares worth $262K. The position accounts for 0.09% of the portfolio, ranked #76.

Cowen Prime Advisors first reported a position in PHAR in Q2 2021 and has held it in 9 quarters since. 2 funds tracked by Wall St. Rank hold PHAR as of Q2 2023.

Cowen Prime Advisors held 22,460 shares of Pharming Group worth $262K as of Q2 2023.
Cowen Prime Advisors left its Pharming Group share count unchanged in Q2 2023.
Pharming Group made up 0.09% of Cowen Prime Advisors's portfolio in Q2 2023, its #76 holding.
Cowen Prime Advisors first reported a position in Pharming Group in Q2 2021 and has held it in 9 quarters since.
2 funds tracked by Wall St. Rank held Pharming Group as of Q2 2023.

Based on Cowen Prime Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.